IP Library Granted Patent US 8,765,743
Granted Patent B2
US 8,765,743 · App. 12/994,253 · Granted Jul 1, 2014

Compounds

Inventors: Ian Robert Baldwin (Stevenage, GB); Kenneth David Down (Stevenage, GB); Paul Faulder (Stevenage, GB); Simon Gaines (Stevenage, GB); Julie Nicole Hamblin (Stevenage, GB); Joelle Le (Stevenage, GB); Christopher James Lunniss (Stevenage, GB); Nigel James Parr (Stevenage, GB); Timothy John Ritchie (Stevenage, GB); Juliet Kay Simpson (Stevenage, GB); Christian Alan Paul Smethurst (Harlow, GB)
Assignee: Glaxosmithkline Intellectual Property Development Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,743
App. No.
12/994,253
Granted
Jul 1, 2014
Kind
B2
Abstract

The invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

Claims (124)

1. A compound of formula (I):

wherein

R 1 is 9- or 10-membered bicyclic heteroaryl wherein the 9- or 10-membered bicyclic heteroaryl contains from one to three heteroatoms independently selected from oxygen and nitrogen and is optionally substituted by C 1-6 alkyl, C 3-6 cycloalkyl, halo or —CN;

R 2 is pyridinyl optionally substituted by one or two substituents independently selected from C 1-6 alkyl, C 2-6 alkenyl, —OR 5 , halo, —(CH 2 ) m NR 6 R 7 , —SO 2 R 8 and phenyl wherein the phenyl is optionally substituted by one or two substituents independently selected from C 1-6 alkyl and —OR 9 ;

R 3 is hydrogen or fluoro;

R 4 is hydrogen, methyl or ethyl;

R 5 is hydrogen, C 1-6 alkyl or 6-membered heterocyclyl wherein the 6-membered heterocyclyl contains one heteroatom selected from oxygen and nitrogen and is optionally substituted by C 1-6 alkyl;

R 6 and R 7 are each independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl or 6-membered heterocyclyl wherein the 6-membered heterocyclyl contains one heteroatom selected from oxygen and nitrogen and is optionally substituted by C 1-6 alkyl, or R 6 and R 7 , together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl or a 1 0-membered bicyclic heterocyclyl wherein the 5- or 6-membered heterocyclyl or the 10-membered bicyclic heterocyclyl optionally contains an oxygen atom, a sulphur atom or a further nitrogen atom and is optionally substituted by one or two substituents independently selected from C 1-6 alkyl; C 3-6 cycloalkyl; halo; oxo; phenyl optionally substituted by halo; pyridinyl; —(CH 2 ) n OR 10 ; —(CH 2 ) p NR 11 R 12 ; —COR 13 ; and —SO 2 R 14 ;

R 8 , R 13 and R 14 are each independently C 1-6 alkyl;

R 9 is hydrogen or C 1-6 alkyl;

R 10 is hydrogen, C 1-6 alkyl or —(CH 2 ) q phenyl;

R 11 and R 12 , together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl optionally containing an oxygen atom; and

m, n, p and q are each independently 0, 1 or 2;

or a salt thereof.

2. A compound according to claim 1 wherein R 1 is 9- or 10-membered bicyclic heteroaryl wherein the 9- or 10-membered bicyclic heteroaryl contains from one to three heteroatoms independently selected from oxygen and nitrogen and is optionally substituted by C 1-6 alkyl.

3. A compound according to claim 1 wherein R 1 is indolyl optionally substituted by C 1-6 alkyl.

4. A compound according to claim 1 wherein R 2 is pyridinyl optionally substituted by one or two substituents independently selected from C 1-6 alkyl and —(CH 2 ),NR 6 R 7 .

5. A compound according to claim 4 wherein R 2 is pyridinyl optionally substituted by C 1-6 alkyl.

6. A compound according to claim 1 wherein R 3 is hydrogen.

7. A compound according to claim 1 wherein R 4 is hydrogen.

8. A compound which is:

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-3-methyl-2-pyridinecarboxamide;

3-bromo-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

5-fluoro-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6[5-methyl-2-(methyloxy)phenyl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-(methyloxy)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-methyl-2-pyridinecarboxamide;

3,5-difluoro-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[1-ethyl-6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-methyl-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1-methyl-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-3-(methyloxy)-2-pyridinecarboxamide;

6-[(dimethylamino)methyl]-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-(4-morpholinylmethyl)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-(1-piperidinylmethyl)-2-pyridinecarboxamide;

3-fluoro-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-3-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-3-(methylsulfonyl)-2-pyridinecarboxamide;

6-chloro-3-fluoro-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-chloro-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-(methylamino)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-[(1-methylethyl)amino]-2-pyridinecarboxamide;

6-(ethylamino)-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-(diethylamino)-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-(cyclopropylamino)-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-(4-methyl-1-piperazinyl)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-(1-pyrrolidinyl)-2-pyridinecarboxamide;

6-(dimethylamino)-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-2-pyridinecarboxamide;

3,6-dichloro-N-[6-(1H-indo1-4-0-1H-indazol-4-yl]-2-pyridinecarboxamide;

3-chloro-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-6-(4-morpholinyl)-2-pyridinecarboxamide;

3-chloro-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-6-(1-piperidinyl)-2-pyridinecarboxamide;

3-chloro-6-(dimethylamino)-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-fluoro-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-[methyl(tetrahydro-2H-pyran-4-yl)amino]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-[(1-methyl-4-piperidinyl)amino]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-(tetrahydro-2H-pyran-4-ylamino)-2-pyridinecarboxamide;

6-chloro-3-(dimethylamino)-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-2-pyridinecarboxamide;

3-(dimethylamino)-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-6-(4-morpholinyl)-2-pyridinecarboxamide;

3-(dimethylamino)-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-6-(1-piperidinyl)-2-pyridinecarboxamide;

3-(dimethylamino)-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-6-(methylamino)-2-pyridinecarboxamide;

3-(dimethylamino)-6-(ethylamino)-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-chloro-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-3-(4-morpholinyl)-2-pyridinecarboxamide;

6-chloro-N-[6-(1H-indol-4-0-1H-indazol-4-yl]-3-(1-piperidinyl)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-5-(4-morpholinyl)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-5-(1-piperidinyl)-2-pyridinecarboxamide;

3-chloro-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-amino-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

5-amino-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-5-methyl-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-methyl-3-pyridinecarboxamide;

3-amino-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-4-(methylamino)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-6-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1-methyl-1H-indol-5-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-(methyloxy)-3-pyridinecarboxamide;

2-(ethyloxy)-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-3-pyridinecarboxamide;

5-bromo-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-(1-pyrrolidinyl)-4-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-(4-morpholinyl)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-oxo-1,6-dihydro-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-(1-pyrrolidinyl)-4-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1-methyl-1H-indazol-4-yl]-6-methyl-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-3-(1-methylethenyl)-2-pyridinecarboxamide;

N- [6-(1H-indol-4-yl)-1H-indazol-4-yl]-3-(1-methylethyl)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-(tetrahydro-2H-pyran-4-yloxy)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-[(4-methyl-1-piperazinyl)methyl]-2-pyridinecarboxamide;

N-[3-fluoro-6-(1H-indol-4-yl)-1H-indazol-4-yl]-3-methyl-2-pyridinecarboxamide;

6-[(4,4-dimethyl-1-piperidinyl)methyl]-N- [6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-[(3,3-dimethyl-1-piperidinyl)methyl]-N- [6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-{[4-(2-methylpropyl)-1-piperazinyl]methyl}-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-{[4-(1-methylethyl)-1-piperazinyl]methyl}-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-{[4-(1-methylethyl)-1-piperidinyl]methyl}-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6({4[2-(4-morpholinyl)ethyl]-1-piperazinyl}methyl)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-(octahydro-4H-1,4-benzoxazin-4-ylmethyl)-2-pyridinecarboxamide;

6-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-{[4-(4-fluorophenyl)-1-piperazinyl]methyl}-N- [6-(1 H-indol-4-yl)-1 H-indazol-4-yl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-(octahydro-2H-pyrido[1,2-a]pyrazin-2-ylmethyl)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-{[2-(1-pyrrolidinylmethyl)-4-morpholinyl]methyl}-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-{[2-(2-methylpropyl)-4-morpholinyl]methyl}-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-{[3-methyl-4-(1-methylethyl)-1 -piperazinyl]methyl}-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-[(3-phenyl-1-piperidinyl)methyl]-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-({2- [(phenyloxy)methyl]-4-morpholinyl}methyl)-2-pyridinecarboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6-({3- [(phenylmethyl)oxy]-1-piperidinyl)methyl}-2-pyridinecarboxamide;

6-{[4-(1-ethylpropyl)-1-piperazinyl]methyl}-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-[(4-cyclopentyl-1-piperazinyl)methyl]-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-methyl-N-[1-methyl-6-(1H-pyrrolo [2,3-b]pyridin-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-(4-morpholinylmethyl)-N-[6-(1H-pyrrolo [2,3-b]pyridin-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-(1-piperidinylmethyl)-N-[6-(1H-pyrrolo [2,3-b]pyridin-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-[(4-methyl-3-oxo-1-piperazinyl)methyl]-N- [6-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-[(4-acetyl-1-piperazinyl)methyl]-N-[6-(1H-pyrrolo [2,3-b]pyridin-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-{[4-(methylsulfonyl)-1-piperazinyl]methyl}-N-[6-(1H-pyrrolo [2,3-b]pyridin-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-[(1,1-dioxido-4-thiomorpholinyl)methyl]-N-[6-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-{[(2R,65)-2,6-dimethyl-4-morpholinyl]methyl}-N-[6-(1H-pyrrolo [2,3-b]pyridin-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-{[3-methyl-4-(1-methylethyl)-1-piperazinyl]methyl}-N-[6-(1H-pyrrolo [2,3-b]pyridin-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-[(4,4-difluoro-1-piperidinyl)methyl]-N- [6-(1H-pyrrolo [2,3-b]pyridin-4-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-(4-morpholinylmethyl)-N-[6-(1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-{[4-(methylsulfonyl)-1-piperazinyl]methyl}-N-[6-(1H-pyrazolo [3 ,4-b]pyridin-5-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-[(1,1-dioxido-4-thiomorpholinyl)methyl]-N-[6-(1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-[(4,4-difluoro-1-piperidinyl)methyl]-N-[6-(1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-{[(2R,65)-2,6-dimethyl-4-morpholinyl]methyl}-N-[6-(1H-pyrazolo [3,4-b]pyridin-5-yl)-1H-indazol-4-yl]-2-pyridinecarboxamide;

6-{[3-methyl-4-(1-methylethyl)-1-piperazinyl]methyl}-N-[6-(1H-pyrazolo [3 ,4-b]pyridin-5 -yl)-1H-indazol-4-yl]-2-pyridinecarboxamide; or

a salt thereof

9. A compound according to claim 1 in the form of a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2014
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
To: GLAXO GROUP LIMITED
Reel/Frame 033605/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2013
From: GLAXO GROUP LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 030615/0036 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2011
From: BALDWIN, IAN ROBERT; DOWN, KENNETH DAVID; FAULDER, PAUL; GAINES, SIMON; HAMBLIN, JULIE NICOLE; LE, JOELLE; LUNNISS, CHRISTOPHER JAMES; PARR, NIGEL JAMES; RITCHIE, TIMOTHY JOHN; SIMPSON, JULIET KAY; SMETHURST, CHRISTIAN ALAN PAUL
To: GLAXO GROUP LIMITED
Reel/Frame 025654/0515 →
Continuity (3)
Provisional Application 61158426 · Mar 9, 2009
Provisional Application 61058956 · Jun 5, 2008
Related Publication 20110118246A1 · May 19, 2011